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Figure 1. General Mechanism of Autophagy. Autophagy is a cellular process
to recycle old or misfolded proteins and organelles for reuse in cellular
biogenesis. First, cargo is enveloped around a double-membrane structure
called the phagopore, which fully closes into a vesicle called the
autophagosome. This then fuses with the lysosome to form an
autophagolysosome. Cargo is broken down into substituent biomolecules to be
reused. Induction of autophagy occurs after treatment in some cancers as an
escape mechanism. Inhibition of autophagy, therefore, would be a suitable
target for combating treatment resistance. Figure adapted from 1.
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Figure 2. Cargo is loaded into autophagosomes by LC3a. LC3a aids in the
elongation of the phagophore and formation of a fully closed autophagosome.
As the phagophore grows, LC3a molecules bind to cargo (e.g. organelles and
protein aggregates) through adapter proteins. These are sequestered to the
inner phagophore membrane and are enclosed inside the autophagosome and
degraded upon fusion with the lysosome. Figure adapted from 2.
Figure 5. SDS-PAGE and BCA assay of recombinant GST-LC3a. (A) SDS-
PAGE of initial purification with 10 mM glutathione did not elute GST-LC3a,
however expression was detected as a protein band near 49 kDa. (B) A follow-
up SDS-PAGE of the resin showed GST-LC3a was still bound. (C) The resin
was incubated with 50 mM glutathione to elute GST-LC3a from the resin. SDS-
PAGE analysis shows characteristic 49 kDa bands in each elution fraction,
indicating GST-LC3a was properly eluted. (D) BCA assay standard curve (blue
dots) and pooled, dialyzed elution fractions (red dot) revealed an undiluted
concentration of 1.16 mg/mL with final yield of 11.6 mg GST-LC3a/L E. coli.
Figure 5. General Protocol for GST-LC3a expression and purification. (1)
BL21 E. coli are transformed with GST-LC3a expression plasmid. (2) Select
transformed colonies with ampicillin agar plates. (3) Inoculate 500 mL culture
with colony and induce protein expression with IPTG. (4) Lyse cells with
lysozyme and tip-sonication then centrifuge. (5) Filter lysate for affinity
purification. (6) Add glutathione agarose resin to lysates to bind GST-LC3a and
purify by gravity column. (7) Recover flow-through containing unbound
proteins. (8) Wash resin with buffer. (9) Elute GST-LC3a glutathione buffer





Figure 6. General solid phase peptide synthesis protocol. (1) Deprotect
resin using 25% piperidine to remove Fmoc protecting groups. (2) Wash resin
5x with DMF to remove released Fmoc groups. (3) Couple Fmoc-amino acid to
resin. HBTU stabilizes carboxylic acid groups and DIEA initiates the coupling
reaction. (4) Wash 5x with DMF to remove excess Fmoc-amino acid and
reagents. (5) Repeat steps 1-4 for each amino acid to build a peptide chain. (6)
After synthesis is complete, deprotect with 25% piperidine and cleave peptide
off the resin with TFA. (7) Cyclize the peptide using DSG.
Figure 7. Purification, identification, and final yields of linear 4B1W. (A) 
HPLC of a gradient from 10%-95% acetonitrile+0.1% TFA over 35 minutes 
revealed a large peak near 8.4 min for each sample. Mass spectrometry (inset) 
confirmed product identity as linear 4B1W. (B) Summary of fourteen 126 µmol 
scale linear 4B1W syntheses yielded of 507.11 mg peptide (average percent 
yield 32.01%). Successful syntheses have mass spectra similar to the inset of 
(A), only the [M+2H]2+ adduct is shown for simplicity.
Conclusion & Future Work
• Linear 4B1W peptide and GST-LC3a produced at high yield and purity
• Cyclization of 4B1W is ongoing
• Cyclic 4B1W will be used in in vitro cell assays & mouse models to evaluate 
the efficacy of autophagy inhibition in different contexts
• Recombinant GST-LC3a will be used as a target for further improvement of 
peptide inhibitors of autophagy
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Figure 3. Cyclic 4B1W structure and computational model of 4B1W:LC3a
interaction. (A) Chemical structure of cyclic 4B1W. Cyclization occurs between
the lysine sidechain and the N-terminus of methionine. (B) Cyclic 4B1W binds
strongly to the LC3a interacting motif, blocking interaction with other autophagy
proteins. As a result, cyclic 4B1W is an inhibitor of cellular autophagy which
sensitizes cancer cells to chemotherapeutics. Figure adapted from 3.
Introduction
• Autophagy is an energy producing mechanism that helps some
cancer cells build resistance to chemotherapeutics.
• Inhibiting autophagy leads to decreased treatment resistance.
• The goals of this work are to:
1) Purify a key autophagy protein to be used to develop future
peptide inhibitors
2) Produce a cyclic peptide inhibitor of the protein target that
will be used to inhibit autophagy in vitro and in vivo
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